Anzeige
Mehr »
Mittwoch, 08.10.2025 - Börsentäglich über 12.000 News
Golden Cross könnte Australiens nächste Goldentdeckung in der Pipeline haben!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AHDP | ISIN: CH0308403085 | Ticker-Symbol: GEM
Frankfurt
08.10.25 | 08:04
0,038 Euro
+9,09 % +0,003
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GENEURO SA Chart 1 Jahr
5-Tage-Chart
GENEURO SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,0390,04408:28

Aktuelle News zur GENEURO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.09.GeNeuro SA Announces the Extension of its Definitive Debt-Restructuring Moratorium303Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court...
► Artikel lesen
16.07.GeNeuro SA Announces the Liquidation of Its French Subsidiary GeNeuro Innovation SAS305Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Lyon Economic...
► Artikel lesen
30.06.GeNeuro Announces Approval of All Resolutions Proposed at Extraordinary General Meeting32869.1% of the Company's share capital was represented at the EGM and resolutions were all unanimously approved Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical...
► Artikel lesen
12.06.GeNeuro SA Announces the Opening of Receivership Proceedings for Its French Subsidiary GeNeuro Innovation SAS403Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that, at the company's...
► Artikel lesen
10.06.GeNeuro SA Announces an Extraordinary Shareholders' Meeting on June 30, 2025360Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that it will hold an...
► Artikel lesen
27.05.GeNeuro SA Announces Definitive Debt-Restructuring Moratorium437Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court...
► Artikel lesen
12.05.GeNeuro SA Announces the Postponement of the Publication of the Company's 2024 Annual Results472Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces the postponement of...
► Artikel lesen
GENEURO Aktie jetzt für 0€ handeln
28.01.GeNeuro SA Announces Renewal of Provisional Debt-Restructuring Moratorium621Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court...
► Artikel lesen
06.12.24New Data Supporting a New Precision Medicine Approach for ALS Patients With GeNeuro's GNK-301 Presented at the 35th International Symposium on ALS/MND934Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases...
► Artikel lesen
9 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1